stockrowDr. Reddy's Laboratories Ltd
RDY Healthcare Drug Manufacturers Specialty & Generic
Dr. Reddy's Laboratories Ltd’s revenue for fiscal 2026 (year ended March 2026) was $3.6 billion, down 6.06% from fiscal 2025.
- Revenue
- −10.1%
- EPS
- −36.8%
- Free cash flow
- −70.5%
- Total debt
- +14.1%
Quarter to September 2026, against a year earlier
Follow RDY
Alert me
Dr. Reddy's Laboratories Ltd (RDY) Revenue
Dr. Reddy's Laboratories Ltd's revenue for fiscal 2026 was $3.6B, down 6.06% from $3.8B in fiscal 2025. Over the twelve months to 30 September 2026 it was $3.3B. Over the past ten years it has ranged from $2.2B (fiscal 2017) to $3.8B (fiscal 2025); the current reading is higher than 92% of that period. Dr. Reddy's Laboratories Ltd ranks 10th of 74 Drug Manufacturers Specialty & Generic companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2026 | $3.6B | (6.06%) |
| FY2025 | $3.8B | 13.76% |
| FY2024 | $3.4B | 11.97% |
| FY2023 | $3.0B | 5.87% |
| FY2022 | $2.8B | 8.94% |
| FY2021 | $2.6B | 12.00% |
| FY2020 | $2.3B | 4.09% |
| FY2019 | $2.2B | 2.02% |
| FY2018 | $2.2B | 0.46% |
| FY2017 | $2.2B | (7.02%) |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $910.4M | 6.73% |
| Jun 2026 | $853.0M | 43.84% |
| Mar 2026 | $593.0M | (39.33%) |
| Dec 2025 | $977.4M | (3.47%) |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| VTRS Viatris Inc. compare | $14.7B |
| ELAN Elanco Animal Health Incorporated compare | $5.0B |
| NBIX Neurocrine Biosciences, Inc. compare | $3.7B |
| RDY Dr. Reddy's Laboratories Ltd | $3.3B |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $3.2B |
| HIMS Hims & Hers Health, Inc. compare | $2.6B |
| ALKS Alkermes plc compare | $1.8B |
| LNTH Lantheus Holdings, Inc. compare | $1.6B |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $946.0M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on RDY
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement